Jennifer Thies

Dr. Jennifer Thies

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
SFSaranna Fanning
Saranna Fanning
HCHaley Cirka
Haley Cirka
JTJennifer Thies
Jennifer Thies
JJJooyoung Jeong
Jooyoung Jeong
SNSarah M. Niemi
Sarah M. Niemi
DSDennis Selkoe
Dennis Selkoe
Synucleinopathy (Parkinson’s disease (PD); Lewy body dementia) disease-modifying treatments represent a huge unmet medical need. Although the PD-causing protein α-synuclein (αS) interacts with lipids and fatty acids (FA) physiologically and pathologically, targeting FA homeostasis for therapeutics is in its infancy. We identified the PD-relevant target stearoyl-coA desaturase: inhibiting monounsaturated FA synthesis reversed PD phenotypes. However, lipid degradation also generates FA pools. Here, we identify the rate-limiting lipase enzyme, LIPE, as a candidate target. Decreasing LIPE in human neural cells reduced αS inclusions. Patient αS triplication vs. corrected neurons had increased pSer129 and insoluble αS and decreased αS tetramer:monomer ratios. LIPE inhibition rescued all these and the abnormal unfolded protein response. LIPE inhibitors decreased pSer129 and restored tetramer:monomer equilibrium in αS E46K-expressing human neurons. LIPE reduction in vivo alleviated αS-induced dopaminergic neurodegeneration in Caenorhabditis elegans. Co-regulating FA synthesis and degradation proved additive in rescuing PD phenotypes, signifying co-targeting as a therapeutic strategy.

15 April 2023 in Cells
Verified
Journal Article
Open access
PDF file
JTJennifer Thies
Jennifer Thies
KWKarolina Willicott
Karolina Willicott
MCMaici Craig
Maici Craig
Madeline Rose GreeneMadeline Rose Greene
Madeline Rose Greene
CDCassandra N. DuGay
Cassandra N. DuGay
KCKim Caldwell
Kim Caldwell
Oxidative stress is a contributing factor to Parkinson’s disease (PD). Considering the prevalence of sporadic PD, environmental exposures are postulated to increase reactive oxygen species and either incite or exacerbate neurodegeneration. We previously determined that exposure to the common soil bacterium, Streptomyces venezuelae (S. ven), enhanced oxidative stress and mitochondrial dysfunction in Caenorhabditis elegans, leading to dopaminergic (DA) neurodegeneration. Here, S. ven metabolite exposure in C. elegans was followed by RNA-Seq analysis. Half of the differentially identified genes (DEGs) were associated with the transcription factor DAF-16 (FOXO), which is a key node in regulating stress response. Our DEGs were enriched for Phase I (CYP) and Phase II (UGT) detoxification genes and non-CYP Phase I enzymes associated with oxidative metabolism, including the downregulated xanthine dehydrogenase gene, xdh-1. The XDH-1 enzyme exhibits reversible interconversion to xanthine oxidase (XO) in response to calcium. S. ven metabolite exposure enhanced XO activity in C. elegans. The chelation of calcium diminishes the conversion of XDH-1 to XO and results in neuroprotection from S. ven exposure, whereas CaCl2 supplementation enhanced neurodegeneration. These results suggest a defense mechanism that delimits the pool of XDH-1 available for interconversion to XO, and associated ROS production, in response to metabolite exposure.

29 October 2018 in Metabolites
Verified
Journal Article
Open access
PDF file
KCKim Caldwell
Kim Caldwell
JTJennifer Thies
Jennifer Thies
Guy A. CaldwellGuy A. Caldwell
Guy A. Caldwell
While progress has been made in discerning genetic associations with Parkinson’s disease (PD), identifying elusive environmental contributors necessitates the application of unconventional hypotheses and experimental strategies. Here, we provide an overview of studies that we conducted on a neurotoxic metabolite produced by a species of common soil bacteria, Streptomyces venezuelae (S. ven), indicating that the toxicity displayed by this bacterium causes stress in diverse cellular mechanisms, such as the ubiquitin proteasome system and mitochondrial homeostasis. This dysfunction eventually leads to age and dose-dependent neurodegeneration in the nematode Caenorhabditis elegans. Notably, dopaminergic neurons have heightened susceptibility, but all of the neuronal classes eventually degenerate following exposure. Toxicity further extends to human SH-SY5Y cells, which also degenerate following exposure. Additionally, the neurons of nematodes expressing heterologous aggregation-prone proteins display enhanced metabolite vulnerability. These mechanistic analyses collectively reveal a unique metabolomic fingerprint for this bacterially-derived neurotoxin. In considering that epidemiological distinctions in locales influence the incidence of PD, we surveyed soils from diverse regions of Alabama, and found that exposure to ~30% of isolated Streptomyces species caused worm dopaminergic neurons to die. In addition to aging, one of the few established contributors to PD appears to be a rural lifestyle, where exposure to soil on a regular basis might increase the risk of interaction with bacteria producing such toxins. Taken together, these data suggest that a novel toxicant within the Streptomyces genus might represent an environmental contributor to the progressive neurodegeneration that is associated with PD.

5 July 2026 in Nicotine & Tobacco Research
Verified
Journal Article
Closed access
JTJennifer Thies
Jennifer Thies
HAHannah J Appleseth
Hannah J Appleseth
NYNaosuke Yamaguchi
Naosuke Yamaguchi
PBPria G Bose
Pria G Bose
ASAdam M Speen
Adam M Speen
MRMeghan Rebuli
Meghan Rebuli
Introduction: E-cigarette use has been linked to respiratory mucosal inflammation and other markers of toxicity. Dual use, or the use of e-cigarettes in combination with conventional cigarettes or other inhaled products has increased in prevalence, but there is limited understanding of the health effects associated with dual use. The aim of this study was to establish whether nasal mucosal cytokine profiles among people who never use tobacco, people who exclusively use electronic cigarettes, and people who dual tobacco product use change over time and whether dual use significantly differs from exclusive e-cigarette use. Methods: This study utilized a repeated sampling study design, collecting nasal epithelial lining fluid from young adult participants (n=64) who never used tobacco, exclusively used electronic cigarettes, and used dual tobacco products, once weekly for four weeks using a remote, non-invasive sampling technique. Nasal mucosal immune mediators and salivary cotinine were then analyzed by ELISA. Results: Differences in mucosal immune mediators were identified between e-cigarette, dual tobacco product and never tobacco product participant groups; however, these markers did not vary across time within group. People who exclusively use e-cigs or dual tobacco products exhibited increased proinflammatory markers compared to people who never use. Chemokine profiles were uniquely altered in the dual tobacco product group. Sex differences were identified in cytokine and chemokine production across groups. Conclusions: These results suggest that remote, non-invasive nasal sampling is adequate for assessing immune profiles from people who use tobacco products and cross-sectional sampling is likely representative of consistent respiratory immune profiles across multiple weeks. Dual product use results in distinct respiratory immune profiles, which suggests that long term disease outcomes may differ from people who exclusively use e-cigs.

19 November 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JTJennifer Thies
Jennifer Thies
HAHannah J. Appleseth
Hannah J. Appleseth
NYNaosuke Yamaguchi
Naosuke Yamaguchi
PBPria G. Bose
Pria G. Bose
ASAdam M. Speen
Adam M. Speen
MRMeghan Rebuli
Meghan Rebuli
Introduction: The use and availability of heated tobacco products has increased globally. However, the health effects of IQOS product use remain contradictory, and the impact of IQOS product use on respiratory health and immune biomarkers is lacking. Industry sponsored studies suggest IQOS products reduce exposure to harmful chemicals compared to conventional cigarettes and show attenuated inflammatory responses compared to cigarette smoke, yet independent research studies indicate exposure to IQOS is still associated with negative health outcomes similar to conventional cigarettes. Clinical data is needed to understand the respiratory health impacts of IQOS use in people who currently smoke cigarettes. Methods: Adults located in Los Angeles, California were recruited for the Adult IQOS Respiratory Study (AIRS, N = 32; 21-65 years). Nasal epithelial lining fluid (NELF) and saliva collected from adults who were willing to incorporate IQOS into their daily habits, were analyzed by multiplex enzyme linked immunosorbent assays for 29 different inflammatory markers or cotinine, respectively. Repeated measures ANOVA were used to identify changes in immune markers across the weekly visits. Linear mixed modelling was used to identify changes in participant cigarette or IQOS HeetStick use over the study period. Day was added as a fixed effect. Results: Between-participants variability in IQOS or cigarette usage was identified (p < 0.0001). IQOS and cigarette use did not significantly change across time and remained stable over the course of the 4-week study period. No significant changes were identified in soluble protein mediators across each week. Cotinine concentrations remained consistent, even when disaggregated by sex and visit. Conclusions: All together, these data highlight that dual product use may be more likely in individuals who smoke cigarettes, particularly over the first month of incorporation, rather than completely switching to IQOS products when provided. Furthermore, incorporating IQOS did not significantly change nicotine exposure or nasal inflammatory biomarkers, suggesting, at least with nicotine exposure and nasal inflammation, that addition of heated tobacco products may not substantially reduce harm. What is already known on this topic: Heated tobacco products are marketed as less harmful and smoke-free alternative products compared to conventional cigarettes; however, lack of respiratory data and contradictory reports suggest they may still pose risks and use may contribute to consequential health impacts. Short-term and industry sponsored studies are available, but limited clinical data exists on the respiratory and immunological impacts of IQOS product use. What this study adds: In the follow repeated measures study, our findings provide clinical evidence there are no significant differences in nasal immune biomarkers in individuals that smoke, who incorporate IQOS into their lifestyles. While each participant varied in their IQOS and cigarette product use, no significant trends were observed over the four-week sampling period in overall IQOS or cigarette use. Additionally, when participants were provided with the IQOS option, they were more inclined to dual use both products rather than switch from cigarettes to only IQOS use in the 4 week period studied. How this study might affect research, practice or policy: The following clinical study suggests there is an increased likelihood of dual use among individuals who are provided alternative tobacco products. Additional studies should consider evaluating health differences, including immunological markers, between individuals who dual use IQOS and other tobacco products, exclusively use IQOS, people who completely switch their product use and people who quit altogether to establish whether IQOS use reduces harmful exposures resulting in differential inflammatory responses when compared to cigarette use.

24 October 2025 in medRxiv
Verified
Preprint
Open access
PDF file
JTJennifer Thies
Jennifer Thies
HAHannah J. Appleseth
Hannah J. Appleseth
NYNaosuke Yamaguchi
Naosuke Yamaguchi
PBPria G. Bose
Pria G. Bose
ASAdam M. Speen
Adam M. Speen
MRMeghan Rebuli
Meghan Rebuli
E-cigarette use has been linked to respiratory mucosal inflammation and other markers of toxicity. Dual use, or the use of e-cigarettes in combination with conventional cigarettes or other inhaled products has increased in prevalence, but there is limited understanding of the health effects associated with dual use. The aim of this study was to establish whether nasal mucosal cytokine profiles among never tobacco users, exclusive electronic cigarette users, and dual tobacco product users change over time and whether dual use significantly differs from exclusive e-cigarette use. This study utilized a repeated sampling study design, collecting nasal epithelial lining fluid from young adult participants (n=64) who were never tobacco users, exclusive electronic cigarette users, and dual tobacco product users, once weekly for four weeks using a remote, non-invasive sampling technique. Nasal mucosal immune mediators and salivary cotinine were then analyzed by ELISA. Differences in mucosal immune mediators were identified between e-cigarette users, dual tobacco product users and never users; however, these markers did not vary across time within group. E-cigarette and dual tobacco product users exhibited increased proinflammatory markers compared to never users. Chemokine profiles were uniquely altered in dual tobacco product users. Sex differences were identified in cytokine and chemokine production across groups. These results suggest that remote, non-invasive nasal sampling is adequate for assessing immune profiles from tobacco product users and cross-sectional sampling is likely representative of consistent respiratory immune profiles across multiple weeks. Dual product use results in distinct respiratory immune profiles, which suggests that long term disease outcomes may differ from exclusive product users. Implications This study demonstrates that respiratory mucosal immune mediator profiles altered with e-cigarette and other tobacco product use are stable over a period of weeks, suggesting that prior cross-sectional study results likely are representative of effects over longer periods of time. This study also shows that dual use of e-cigarettes with other tobacco products induces a unique elevated chemokine profile compared to sole e-cigarette use, while retaining similar elevated inflammatory cytokine profiles. This suggests that dual product use may induce differential long-term effects that sole product use.